Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capecitabine/Cyclophosphamide - Sanofi

Next Previous
Search
Drug Profile

Capecitabine/Cyclophosphamide - Sanofi

Alternative Names: Cyclophosphamide/Capecitabine - Sanofi; SAR-439281

Latest Information Update: 15 Feb 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Class Antineoplastics; Carbamates; Cyclophosphamides; Myeloablative agonists; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Alkylating agents; Antimetabolites; DNA cross linking agents; DNA synthesis inhibitors; Immunomodulators; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 15 Feb 2022 Discontinued - Phase-II for Breast cancer (Metastatic disease, Second-line therapy or greater) in India (PO), prior to February 2022
  • 15 Feb 2022 No development reported - Phase-II for Breast cancer (Metastatic disease, Second-line therapy or greater) in India (PO), prior to February 2022
  • 06 Nov 2017 Sanofi completes a phase II trial in Breast cancer (Metastatic disease, Second-line therapy or greater) in India (PO) (NCT02664103)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top